Detalhe da pesquisa
1.
Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre.
Support Care Cancer;
30(2): 1841-1852, 2022 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34609585
2.
A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation.
Clin Infect Dis;
73(11): e4269-e4277, 2021 12 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33175132
3.
Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.
Intern Med J;
51(2): 280-283, 2021 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33631863
4.
Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre.
Support Care Cancer;
26(3): 997-1003, 2018 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29018966
5.
The development of a home-based therapeutic platform for multiple myeloma.
Expert Rev Hematol;
14(12): 1129-1135, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34936527
6.
The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Clin Lymphoma Myeloma Leuk;
14(4): 291-6, 2014 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24629850
7.
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Leuk Lymphoma;
54(7): 1465-72, 2013 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23121086